Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80366 |
Name | desmoid tumor |
Definition | A connective tissue benign neoplasm that occur most often in the abdomen, arms and legs. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation benign neoplasm organ system benign neoplasm musculoskeletal system benign neoplasm connective tissue benign neoplasm desmoid tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CTNNB1 S45F | Imatinib | desmoid tumor | sensitive | detail... |
CTNNB1 act mut | Imatinib | desmoid tumor | sensitive | detail... |
CTNNB1 T41A | Imatinib | desmoid tumor | sensitive | detail... |
CTNNB1 mutant | N/A | desmoid tumor | not applicable | detail... |
APC mutant | N/A | desmoid tumor | not applicable | detail... |
CTNNB1 T41A | BMS-906024 | desmoid tumor | predicted - sensitive | detail... |
APC inact mut | BMS-906024 | desmoid tumor | predicted - sensitive | detail... |
APC T1556Nfs*3 | Celecoxib + Nirogacestat | desmoid tumor | predicted - sensitive | detail... |
APC inact mut | Nirogacestat | desmoid tumor | predicted - sensitive | detail... |
APC R1450* APC LOH | Nirogacestat | desmoid tumor | predicted - sensitive | detail... |
APC mutant | Nirogacestat | desmoid tumor | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03459469 | Phase I | BC2059 | Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 | Completed | USA | CAN | 0 |
NCT03785964 | Phase III | Nirogacestat | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi) | Active, not recruiting | USA | NLD | ITA | GBR | DEU | CAN | BEL | 0 |
NCT03886311 | Phase II | Nivolumab + Talimogene laherparepvec + Trabectedin | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) | Recruiting | USA | 0 |
NCT04195399 | Phase II | Nirogacestat | A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04871282 | Phase II | AL102 | A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | ESP | DEU | BEL | AUS | 1 |
NCT05879146 | Phase II | Nirogacestat | Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study | Not yet recruiting | USA | 0 |
NCT05949099 | Phase II | Nirogacestat | Study of Cryoablation and Nirogacestat for Desmoid Tumor | Recruiting | USA | 0 |